1446358-48-0

Basic information

• Product Name: 3-(3-(4-chloro-5-fluoropyrimidin-2-yl)-1-(2-fluorobenzyl)-1H-pyrazol-5-yl)isoxazole
• Synonyms: 3-(3-(4-chloro-5-fluoropyrimidin-2-yl)-1-(2-fluorobenzyl)-1H-pyrazol-5-yl)isoxazole
• CAS NO: 1446358-48-0
• Molecular Weight: 373.749
• Mol File: 1446358-48-0.mol
• Article Data: 9

Chemical Properties

• CAS DataBase Reference: 3-(3-(4-chloro-5-fluoropyrimidin-2-yl)-1-(2-fluorobenzyl)-1H-pyrazol-5-yl)isoxazole(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(3-(4-chloro-5-fluoropyrimidin-2-yl)-1-(2-fluorobenzyl)-1H-pyrazol-5-yl)isoxazole(1446358-48-0)
• EPA Substance Registry System: 3-(3-(4-chloro-5-fluoropyrimidin-2-yl)-1-(2-fluorobenzyl)-1H-pyrazol-5-yl)isoxazole(1446358-48-0)

Safety Data

• Hazardous Substances Data: 1446358-48-0(Hazardous Substances Data)

Upstream product

• 1330044-12-6 2-ethynyl-5-fluoro-4-methoxypyrimidine 
• 1330044-11-5 5-fluoro-4-methoxy-2-[(trimethylsilyl)ethynyl]pyrimidine 
• 1446358-49-1 3-(3-(5-fluoro-4-methoxypyrimidin-2-yl)-1-(2-fluorobenzyl)-1H-pyrazol-5-yl)isoxazole 
• 1446359-44-9 3-(3-(4-chloro-5-fluoro-6-methoxypyrimidin-2-yl)-1-(2-fluorobenzyl)-1H-pyrazol-5-yl)isoxazole 
• 1446359-43-8 3-(3-(4,6-dichloro-5-fluoropyrimidin-2-yl)-1-(2-fluorobenzyl)-1H-pyrazol-5-yl)isoxazole 
• 1579999-84-0 C₉H₈NO₅^(1-)*Li⁽¹⁺⁾ 
• 88511-37-9 1-(isoxazol-3-yl)ethan-1-one 
• 1354041-91-0 5-fluoro-2-(1-(2-fluorobenzyl)-5-(isoxazol-3-yl)-1H-pyrazol-3-yl)-pyrimidin-4-ol 
• 1354044-23-7 1-(2-fluorobenzyl)-5-(isoxazol-3-yl)-1H-pyrazole-3-carboximidamide 
• 1354044-05-5 1-(2-fluorobenzyl)-5-(isoxazol-3-yl)-1H-pyrazole-3-carboximidamide hydrochloride 
• 1446353-66-7 C₁₄H₉FN₄O 
• 1446353-53-2 C₁₄H₁₀FN₃O₃ 

Downstream Products

• 1446358-49-1 3-(3-(5-fluoro-4-methoxypyrimidin-2-yl)-1-(2-fluorobenzyl)-1H-pyrazol-5-yl)isoxazole 
• 1446358-50-4 C₁₇H₁₃F₂N₇O 
• 1446359-60-9 C₁₉H₁₂F₂N₆O 
• 1446359-52-9 C₁₈H₁₀F₂N₆O 
• 1446359-91-6 C₂₄H₂₀F₂N₆O₃ 

Relevant articles and documents

Discovery of CYR715: A novel carboxylic acid-containing soluble guanylate cyclase stimulator

Soluble guanylate cyclase (sGC) is a clinically validated therapeutic target in the treatment of pulmonary hypertension. Modulators of sGC have the potential to treat diseases that are affected by dysregulation of the NO-sGC-cGMP signal transduction pathw

SOLID DISPERSIONS COMPRISING A SGC STIMULATOR

The present invention relates to solid dispersions of amorphous 1,1,1,3,3,3-hexafluoro-2-(((5-fluoro-2-(1-(2-fluorobenzyl)-5-(isoxazol-3-yl)-1H-pyrazol-3-yl)pyrimidin-4-yl)amino)methyl)propan-2-ol (Compound I) or a pharmaceutically acceptable salt thereof. It also relates to pharmaceutical compositions and pharmaceutical oral dosage unit forms comprising them, and their uses thereof.

Discovery of IWP-051, a Novel Orally Bioavailable sGC Stimulator with Once-Daily Dosing Potential in Humans

In recent years, soluble guanylate cyclase (sGC, EC 4.6.1.2) has emerged as an attractive therapeutic target for treating cardiovascular diseases and diseases associated with fibrosis and end-organ failure. Herein, we describe our design and synthesis of